Literature DB >> 23618862

YM155 induces caspase-8 dependent apoptosis through downregulation of survivin and Mcl-1 in human leukemia cells.

Weiying Feng1, Akira Yoshida, Takanori Ueda.   

Abstract

Survivin, a member of the inhibitor of apoptosis protein (IAP) family, is highly expressed in various kinds of tumors. In the present study, we investigated the cytotoxic mechanism of YM155, a unique small-molecule inhibitor of survivin, in human myelogenous leukemia cells. YM155 potently inhibited the cell growth of HL-60 and U937 cells with the half-maximal inhibitory concentration (IC50) value of 0.3 nM and 0.8 nM, respectively. YM155 significantly suppressed the levels of mRNA expression and protein of survivin in HL-60 and U937 cells. In addition, we also found that YM155 down-regulated the level of Mcl-1, another critical anti-apoptotic protein, in both HL-60 and U937 cells. Treatment of HL-60 and U937 cells with YM155 induced apoptosis concomitant with the activation of caspase-8 and caspase-3. Interestingly, we have found that caspase-8 inhibitor Z-IETD-FMK strongly inhibited YM155-induced apoptosis in HL-60 and U937 cells. When cells were pretreated with Z-IETD-FMK, the activation of caspase-3 was completely abolished, suggesting that caspase-8 may be involved in the activation of caspase-3 during YM155-induced apoptosis. We demonstrated for the first time that YM155 induces caspase-8 dependent apoptosis through downregulation of survivin and Mcl-1 in human leukemia cells.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23618862     DOI: 10.1016/j.bbrc.2013.04.036

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.322


  17 in total

Review 1.  Survivin as a novel target protein for reducing the proliferation of cancer cells.

Authors:  Dongyu Li; Chenghao Hu; Huibin Li
Journal:  Biomed Rep       Date:  2018-03-13

2.  Implementation of validated pharmacodynamic assays in multiple laboratories: challenges, successes, and limitations.

Authors:  Robert Kinders; Kate Ferry-Galow; Lihua Wang; Apurva K Srivastava; Jiuping Jay Ji; Ralph E Parchment
Journal:  Clin Cancer Res       Date:  2014-05-15       Impact factor: 12.531

3.  Knockout Of BIRC5 Gene By CRISPR/Cas9 Induces Apoptosis And Inhibits Cell Proliferation In Leukemic Cell Lines, HL60 And KG1.

Authors:  Manizheh Narimani; Mohammadreza Sharifi; Ali Jalili
Journal:  Blood Lymphat Cancer       Date:  2019-11-27

4.  AML sensitivity to YM155 is modulated through AKT and Mcl-1.

Authors:  Rosalia de Necochea-Campion; Carlos J Diaz Osterman; Heng-Wei Hsu; Junjie Fan; Saied Mirshahidi; Nathan R Wall; Chien-Shing Chen
Journal:  Cancer Lett       Date:  2015-06-25       Impact factor: 9.756

5.  Targeting the proliferative and chemoresistant compartment in chronic lymphocytic leukemia by inhibiting survivin protein.

Authors:  N Purroy; P Abrisqueta; J Carabia; C Carpio; E Calpe; C Palacio; J Castellví; M Crespo; F Bosch
Journal:  Leukemia       Date:  2014-03-12       Impact factor: 12.883

6.  YM155 potently kills acute lymphoblastic leukemia cells through activation of the DNA damage pathway.

Authors:  Bill H Chang; Kara Johnson; Dorian LaTocha; Joelle S J Rowley; Jade Bryant; Russell Burke; Rebecca L Smith; Marc Loriaux; Markus Müschen; Charles Mullighan; Brian J Druker; Jeffrey W Tyner
Journal:  J Hematol Oncol       Date:  2015-04-22       Impact factor: 23.168

7.  Targeting caspase-6 and caspase-8 to promote neuronal survival following ischemic stroke.

Authors:  A P Shabanzadeh; P M D'Onofrio; P P Monnier; P D Koeberle
Journal:  Cell Death Dis       Date:  2015-11-05       Impact factor: 8.469

8.  Dioxonaphthoimidazoliums AB1 and YM155 disrupt phosphorylation of p50 in the NF-κB pathway.

Authors:  Si Han Sherman Ho; Azhar Ali; Tan Min Chin; Mei Lin Go
Journal:  Oncotarget       Date:  2016-03-08

9.  YM155, a survivin suppressant, triggers PARP-dependent cell death (parthanatos) and inhibits esophageal squamous-cell carcinoma xenografts in mice.

Authors:  Nan Zhao; Yousheng Mao; Gaijing Han; Qiang Ju; Lanping Zhou; Fang Liu; Yang Xu; Xiaohang Zhao
Journal:  Oncotarget       Date:  2015-07-30

10.  Overexpression of CCDC34 in colorectal cancer and its involvement in tumor growth, apoptosis and invasion.

Authors:  Wei Geng; Wei Liang; Yanan Fan; Zhibin Ye; Lixiao Zhang
Journal:  Mol Med Rep       Date:  2017-10-24       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.